BioSyent to Attend Planet MicroCap Showcase
BioSyent to Attend Planet MicroCap Showcase
MISSISSAUGA, Ontario, April 23, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", TSX Venture: RX) is pleased to announce that it will be attending the Planet MicroCap Showcase in Las Vegas, Nevada between April 30th – May 2nd at the Paris Hotel & Casino. Mr. René Goehrum, President and CEO of BioSyent, will attend a Fireside Q&A session for investors at the conference on Wednesday, May 1st at 2:30pm PDT.
安大略省密西沙加，2024年4月23日（GLOBE NEWSWIRE）——BioSyent Inc.（“BioSyent”，多倫多證券交易所風險投資代碼：RX）欣然宣佈，它將參加4月30日在內華達州拉斯維加斯舉行的Planet MicroCap展示會第四 — 5 月 2 日和 在巴黎酒店和賭場。BioSyent總裁兼首席執行官雷內·戈赫魯姆先生將在5月1日星期三的會議上出席爐邊投資者問答環節st 太平洋夏令時間下午 2:30。
Mr. Goehrum will also be available to meet with investors on a one-on-one basis during the conference on Thursday, May 2nd between 8:00am – 5:00pm PDT. These one-on-one meetings can be requested by registered attendees through the conference portal online:
在5月2日星期四的會議期間，Goehrum先生還將與投資者進行一對一的會面。和 太平洋夏令時間上午 8:00 至下午 5:00 之間。註冊的與會者可以通過會議門戶在線申請這些一對一的會議：
About BioSyent Inc.
關於 BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty, and international business units.
BioSyent在多倫多證券交易所風險交易所上市，交易代碼爲 “RX”，是一家以盈利爲導向的增長型專業製藥公司，專注於許可或收購已成功開發、安全有效且在改善患者生活方面有良好記錄的創新藥物和其他醫療保健產品。BioSyent通過其社區、專業和國際業務部門銷售其產品，爲治療這些患者的醫療保健專業人員提供支持。
As of the date of this press release, the Company has 11,605,373 common shares outstanding.
截至本新聞稿發佈之日，該公司已發行11,605,373股普通股。
For a direct market quote for the TSX Venture Exchange and other Company financial information please visit .
如需多倫多證券交易所風險交易所的直接市場報價和其他公司財務信息，請訪問。
For further information please contact:
欲了解更多信息，請聯繫：
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web:
René C. Goehrum 先生
總裁兼首席執行官
BioSyent Inc.
電子郵件：investors@biosyent.com
電話：905-206-0013
網頁：
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
本新聞稿可能包含前瞻性的信息或陳述。此處的內容代表我們截至發佈之日的判斷，並且存在風險和不確定性，這些風險和不確定性可能會導致實際結果或結果與前瞻性信息或陳述存在重大差異。潛在風險可能包括但不限於與臨床試驗、產品開發、未來收入、運營、盈利能力和獲得監管部門批准相關的風險。
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
多倫多證券交易所風險交易所及其監管服務提供商（該術語在多倫多證券交易所風險交易所的政策中定義）均不對本新聞稿的充分性或準確性承擔責任。
譯文內容由第三人軟體翻譯。